Device Trial Radar · NCT01919320
SynCardia Companion 2 Driver System Post Approval Study Protocol With INTERMACS™-Based Data Collection
Last checked: Nov 20, 2026Latest source record: Oct 23, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
500
Planned (sponsor's estimate)
Start
Dec 2013
Primary completion
Dec 2022
Study completion Jul 2023
Sponsor
- Lead sponsor
- SynCardia Systems. LLCNot on our public-company list
- Sponsor type
- Industry
- First posted
- Aug 9, 2013
Design
- Study type
- Observational
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study Purpose The purpose of this PAS is to confirm that patients implanted with the temporary Total Artificial Heart (TAH-t) and supported with the Companion 2 Driver System have outcomes similar to those patients implanted with the TAH-t and supported with the CSS Console. The data collection mechanism for this study is the INTERMACS Registry. Study Objectives Primary Objective 1: To confirm that patients implanted with the TAH-t and supported by the Companion 2 Driver System have outcomes similar to those patients implanted with the TAH-t and supported by the CSS Console. Primary Objective 2: To compare positive outcome rates for all TAH-t patients entered in the Intermacs Registry initially supported with the Companion 2 Driver System to positive outcome rates for all TAH-t patients initially supported by the CSS Console. Primary Objective 3: To review additional data (patient survival, adverse event rates and bridge to transplant rates) to support the conclusion that the use of an artificial heart is reasonable and necessary for the treatment of irreversible biventricular failure in Medicare/Medicaid patients. Secondary Objective: * To evaluate the incidence of adverse events (AEs). The AEs will follow the definitions in the INTERMACS Registry. Study Hypothesis: Primary Objective 1 The primary hypothesis is that the positive outcome rate (defined as transplant , transfer to the Freedom Driver System support, or continuing on implant driver support, whichever occurs first; assessed at three and six months post-implant) for patients supported with the Companion 2 Driver System is non-inferior to the survival rate for patients supported with the Circulatory Support System (CSS) Console. Data Collection The data will be collected as defined in the INTERMACS Protocol and the patients will be followed at one week, one month, three months and six months or until their study endpoint is reached. Data Analysis Primary Objective 1: Data analysis will provide descriptive statistics on enrollment, adverse events, and outcomes for TAH-t patients who were implanted while supported with the Companion 2 Driver System compared to TAH-t patients who were implanted while supported with the CSS Console. Primary Objective 2: Data analysis will provide descriptive statistics on enrollment, adverse events, and outcomes for all TAH-t patients enrolled in the INTERMACS Registry. Phase I as described above was completed; Phase II of Study design is under review by FDA with anticipated initiation in early 2021.
Conditions
- Bi-ventricular Failure
Interventions
C2 Driver System TAH-t PatientsDevice
Comparison of two pneumatic drivers supporting the SynCardia TAH-t
CSS Console TAH-t PatientsDevice
Comparison of two pneumatic drivers supporting the SynCardia TAH-t.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Positive outcome rates at three months and six months Post TAH-t Implant (Concurrent Cohort)Time frame: Three and Six Months Post-TAH-t Implant
- Positive outcome rates at three months and six months Post TAH-t Implant (Cumulative Cohort)Time frame: Three and Six Months Post-TAH-t Implant
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.